|
Market Closed -
Other stock markets
|
After market 04:49:50 pm | |||
| 65.54 USD | +1.17% |
|
65.39 | -0.23% |
| May. 02 | UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating | MT |
| May. 01 | Deutsche Bank Adjusts Price Target on Gilead Sciences to $73 From $75 | MT |
Gilead Sciences, Inc. revised earnings guidance for the full year 2024. For the year, the company expects product sales to be $27,100 million to $27,500 million same as previously expected. Diluted EPS to be $0.10 to $0.50 compared to previous guidance of $5.15 to $5.55.
GAAP projected operating income to be $1,900 million to $2,400 million compared to previous guidance of $8,700 million to $9,200 million.
| 1st Jan change | Capi. | |
|---|---|---|
| -19.10% | 80.78B | |
| +31.52% | 662B | |
| +21.96% | 546B | |
| -5.21% | 359B | |
| +17.02% | 323B | |
| +5.01% | 289B | |
| +13.68% | 234B | |
| +3.81% | 198B | |
| -10.63% | 194B | |
| +3.98% | 167B |
GILEAD SCIENCES, INC. 
